Colleen Moretti

Articles

Radiotherapy Use in ATLAS Is Reflective of Current Guidance in High-Risk Localized Prostate Cancer

June 14th 2022

Apalutamide plus androgen deprivation therapy and radiotherapy was evaluated in patients with high- and very high–risk localized or locally advanced prostate cancer, with RT schedules that are reflective of recommended practice guidelines.

Mobocertinib May Have Limited Intracranial Activity in EGFR Exon 20 Insertion+ NSCLC With Baseline Brain Mets

June 6th 2022

Mobocertinib may have limited intracranial activity in patients with EGFR exon 20 insertion–positive, non–small cell lung cancer with brain metastases at baseline, given the numerically lower response rate observed with the agent in this population.

Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCL

June 3rd 2022

Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.

Black Patients Less Likely to Trust Clinical Trials in Breast Cancer

May 26th 2022

Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.

Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia

March 11th 2022

Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.

Cabozantinib After Immunotherapy Failure Reassured as Safe, Feasible for mRCC

February 19th 2022

Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.

TACE Combined With Lenvatinib and Sunitinib May Be a Safe, Tolerable Treatment Option for Unresectable HCC

January 21st 2022

Transarterial chemoembolization combined with lenvatinib plus sintilimab was safe and effective for patients with unresectable hepatocellular carcinoma.

Ibrutinib Plus Rituximab Confers Superior PFS to FCR in Previously Untreated CLL

December 13th 2021

The results also demonstrated no significant difference in overall survival benefit between the treatment groups. However, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

Updated Study Results Show Durable Responses in CLL After Fixed-Duration Ibrutinib-Venetoclax Based on Undetectable MRD

December 11th 2021

The use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia continues to provide deep, durable responses, according to updated results from the MRD cohort of the phase 2 CAPTIVATE trial.

Sabizabulin Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer

September 13th 2021

Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma

June 12th 2021

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

Selpercatinib Effective in RET Fusion–Positive NSCLC, Irrespective of Prior Therapies

June 5th 2021

Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Aumolertinib Prolongs Survival, Duration of Response in NSCLC

June 5th 2021

Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.

Pralsetinib Is Tolerable, Durable in RET Fusion-Positive NSCLC

June 4th 2021

Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.

Nivolumab/Cabozantinib Combo Improves Quality of Life in Advanced RCC

February 12th 2021

February 12, 2021 - Patients with advanced renal cell carcinoma reported improved health-related quality of life when treated with nivolumab plus cabozantinib compared with sunitinib

Immuno-Oncology Therapies Could Be More Beneficiary for Small Cell Lung Cancer

January 28th 2021

January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.

Nivolumab Improves Quality of Life in Patients with Esophageal/Gastroesophageal Cancer

January 15th 2021

January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.

Pregnancy May Be Difficult for Breast Cancer Survivors, But Often Produces Healthy Babies with No Impact on Long-Term Survival

December 10th 2020

December 10, 2020 - Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.